December 23, 2021
What are the key characteristics of hybrid direct-to-patient studies and supply chain structures that can make them a standard consideration for clinical trial adoption? 4G Clinical's Neta Bendelac recently wrote an article for Pharmaceutical Commerce addressing this very topic.
Here's a short excerpt:
Prior to Covid, adoption of the DtP design was slow. Pharma sponsors only stood up DtP studies when circumstances dictated their need, but the fallout of the virus changed everything. Vulnerable patient populations demanded the flexibility of access afforded to them by DtP trials to maintain safety and convenience. And as preferences for clinical trial participation changed, sponsors and contract research organizations (CROs) had to adapt. They recognized that DtP trials can improve enrollment, ease patient burden and create greater transparency in the investigational medicinal product (IMP) journey from the clinical site to patients’ homes. Hybrid DtP trial models combine the support and reliability of on-site clinics with more patient-centric comforts afforded by DCTs.
View the complete article at Pharmaceutical Commerce.